Daniel Menold News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Assenagon Asset Management S.A. purchased a new position in shares of CymaBay Therapeutics, Inc. (NASDAQ:CBAY – Free Report) during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 746,353 shares of the biopharmaceutical company’s stock, valued at approximately $17,629,000. Assenagon Asset Management […]

Monashee Investment Management LLC acquired a new stake in CymaBay Therapeutics, Inc. (NASDAQ:CBAY – Free Report) in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm acquired 75,000 shares of the biopharmaceutical company’s stock, valued at approximately $1,118,000. Several other hedge funds and other […]

Monashee Investment Management LLC acquired a new stake in shares of CymaBay Therapeutics, Inc. (NASDAQ:CBAY – Free Report) in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 75,000 shares of the biopharmaceutical company’s stock, valued at approximately $1,118,000. Monashee Investment […]

CymaBay Therapeutics, Inc. (NASDAQ:CBAY – Get Free Report) has received an average rating of “Buy” from the thirteen research firms that are presently covering the firm, Marketbeat Ratings reports. Twelve analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. The average twelve-month price target […]

CymaBay Therapeutics (NASDAQ:CBAY – Get Free Report)‘s stock had its “overweight” rating reaffirmed by equities researchers at Cantor Fitzgerald in a report released on Thursday, Benzinga reports. They currently have a $15.00 target price on the biopharmaceutical company’s stock. Cantor Fitzgerald’s target price suggests a potential upside of 9.41% from the company’s previous close. Other […]